Literature DB >> 9007744

Familial Lafora body disease of late onset: report of four cases in one family and a review of the literature.

D R Footitt1, N Quinn, R S Kocen, B Oz, F Scaravilli.   

Abstract

Lafora body disease is one cause of progressive myoclonus epilepsy. It typically presents in the second decade with generalized seizures, myoclonus and then intellectual decline. Death is usual within 10 years. Diagnosis may be made by biopsy of skin, muscle, liver or brain. We present four siblings who were normal until their mid-twenties, but then developed intellectual decline, followed by myoclonus. Although a rare form of Lafora body disease has been described that follows a more benign course, may be of later onset, and whose pathology is subtly different, this family is so far unique in terms of the late presentation of otherwise typical Lafora body disease.

Entities:  

Mesh:

Year:  1997        PMID: 9007744     DOI: 10.1007/s004150050048

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  4 in total

Review 1.  Lafora disease: epidemiology, pathophysiology and management.

Authors:  Thomas S Monaghan; Norman Delanty
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

2.  Diagnosis of Lafora Disease by Skin Biopsy.

Authors:  Prasath Sathiah; Debasis Gochhait; Priyadarshini Dehuri; Hema Subramanian
Journal:  J Clin Diagn Res       Date:  2017-09-01

3.  Role of levetiracetam in refractory seizures due to a rare progressive myoclonic epilepsy: Lafora body disease.

Authors:  Mubashira Hashmi; Feroza Saleem; Muhammad Shahid Mustafa; Mughis Sheerani; Zeeshan Ehtesham; Khurram Siddiqui
Journal:  BMJ Case Rep       Date:  2010-11-05

4.  Novel mutation in the NHLRC1 gene in a Malian family with a severe phenotype of Lafora disease.

Authors:  M Traoré; G Landouré; W Motley; M Sangaré; K Meilleur; S Coulibaly; S Traoré; B Niaré; F Mochel; A La Pean; A Vortmeyer; H Mani; K H Fischbeck
Journal:  Neurogenetics       Date:  2009-03-26       Impact factor: 2.660

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.